NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY

Francis Joseph Giles

NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY

Francis Joseph Giles

Medicine

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Abstract
Volume	95
Publication status	Published - 1 Jun 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{98074daa24404f22abd9bd36357cefb6,

title = "NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY",

author = "Giles, {Francis Joseph}",

year = "2010",

month = jun,

day = "1",

language = "English (Ireland)",

volume = "95",

type = "Other",

}